Steatotic liver disease: Know your enemies

Steatotic liver disease: Know your enemies

Bibliographic Details
Main Author:	Lung-Yi Mak
Format:	Article
Language:	English
Published:	Korean Association for the Study of the Liver 2024-04-01
Series:	Clinical and Molecular Hepatology
Subjects:	fatty liver hepatocellular carcinoma cardiovascular diseases malignancy cohort effect
Online Access:	http://e-cmh.org/upload/pdf/cmh-2024-0078.pdf

Similar Items

Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
by: Byeong Geun Song, et al.
Published: (2024-03-01)

Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease
by: Jeong-Ju Yoo, et al.
Published: (2023-05-01)

In response to: Steatotic liver disease-know your enemies
by: Michael H. Le, et al.
Published: (2024-04-01)

Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors
by: Yoshihisa Takahashi, et al.
Published: (2023-10-01)

Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
by: Yumin Wang, et al.
Published: (2024-01-01)

Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis
by: Jun-Hyuk Lee, et al.
Published: (2023-12-01)

Association between smoking and non-alcoholic fatty liver disease in Southeast Asia
by: Hassan Mumtaz, et al.
Published: (2022-12-01)

Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort studyResearch in context
by: Joon Ho Moon, et al.
Published: (2023-11-01)

Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
by: Eileen L. Yoon, et al.
Published: (2024-01-01)

Waiting for the changes after the adoption of steatotic liver disease
by: Eileen L. Yoon, et al.
Published: (2023-10-01)

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
by: Yuri Cho, et al.
Published: (2023-02-01)

Screening for aberrantly methylated and differentially expressed genes in nonalcoholic fatty liver disease of hepatocellular carcinoma patients with cirrhosis
by: Guizhi Zhang, et al.
Published: (2022-11-01)

Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
by: Ji-Qiao Zhu, et al.
Published: (2024-04-01)

Linking fatty liver diseases to hepatocellular carcinoma by hepatic stellate cells
by: Liang'en Chen, et al.
Published: (2024-03-01)

Hepatocellular Carcinoma-Liver Resections
by: Sefa Tüzün, et al.
Published: (2015-03-01)

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
by: Gi-Ae Kim, et al.
Published: (2023-10-01)

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
by: Hidekatsu Yanai, et al.
Published: (2023-10-01)

Lipid alterations in chronic liver disease and liver cancerKey points
by: Bichitra Paul, et al.
Published: (2022-06-01)

Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?
by: Xuan-vinh Kevin Nguyen, et al.
Published: (2022-09-01)

The Current View of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma
by: Tomomi Kogiso, et al.
Published: (2021-01-01)

Fatty Liver Disease, Metabolism and Alcohol Interplay: A Comprehensive Review
by: Aitor Odriozola, et al.
Published: (2023-04-01)

Ferroptosis as an emerging therapeutic target in liver diseases
by: Yuzhen Lu, et al.
Published: (2023-05-01)

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
by: Margaret LP Teng, et al.
Published: (2023-04-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
by: Wah-Kheong Chan, et al.
Published: (2023-09-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
by: Katharina Staufer, et al.
Published: (2023-07-01)

Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: The Next Threat after Viral Hepatitis
by: Mohamed Salaheldin, et al.
Published: (2023-08-01)

Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies
by: Yi Zhang, et al.
Published: (2024-03-01)

Shared Genes and Molecular Mechanisms between Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma Established by WGCNA Analysis
by: He He, et al.
Published: (2023-09-01)

Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease
by: Zihan Wei, et al.
Published: (2020-02-01)

The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque
by: Yunqian Huang, et al.
Published: (2023-11-01)

Neutrophil‐lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with non‐alcoholic fatty liver disease
by: Claire E. Thomas, et al.
Published: (2023-02-01)

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
by: Shang-Chin Huang, et al.
Published: (2023-04-01)

Associations of non‐alcoholic fatty liver disease and cirrhosis with liver cancer in European and East Asian populations: A Mendelian randomization study
by: Yunyang Deng, et al.
Published: (2024-01-01)

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?
by: Ju Hyun Shim
Published: (2020-04-01)

Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang
by: Yanbo Guo, et al.
Published: (2022-06-01)

Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
by: Jae Seung Lee, et al.
Published: (2021-09-01)

Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies
by: Erica Vetrano, et al.
Published: (2023-02-01)

The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients
by: Natasa Paklar, et al.
Published: (2023-11-01)

Understanding the Role of Perilipin 5 in Non-Alcoholic Fatty Liver Disease and Its Role in Hepatocellular Carcinoma: A Review of Novel Insights
by: Paola Berenice Mass Sanchez, et al.
Published: (2021-05-01)

Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis
by: Lili Liu, et al.
Published: (2023-01-01)